Advertisement

 

 

Hospitalization and medical cost of patients with elevated serum N-terminal pro-brain natriuretic peptide levels.

Hospitalization and medical cost of patients with elevated serum N-terminal pro-brain natriuretic peptide levels.
Author Information (click to view)

Kitagawa T, Oda N, Mizukawa M, Hidaka T, Naka M, Nakayama S, Kihara Y,


Kitagawa T, Oda N, Mizukawa M, Hidaka T, Naka M, Nakayama S, Kihara Y, (click to view)

Kitagawa T, Oda N, Mizukawa M, Hidaka T, Naka M, Nakayama S, Kihara Y,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

PloS one 2018 01 0513(1) e0190979 doi 10.1371/journal.pone.0190979
Abstract
BACKGROUND
Patients with heart failure (HF) are reportedly at high risk for ‘all-cause’ re-hospitalization. A biomarker for HF, N-terminal pro-brain natriuretic peptide (NT-proBNP), enables to simply detect patients with possible HF (pHF). We examined the hospitalization and medical cost of Japanese patients detected by an elevated serum NT-proBNP, and also evaluated the effects of institutional team approaches for HF on their all-cause hospitalizations.

METHODS
We retrospectively extracted all adult patients with serum NT-proBNP ≥400 pg/ml measured between January and March 2012 in Hiroshima University Hospital as pHF-positive patients. We studied their all-cause hospitalization records during the past 3-year period. We also extracted all pHF-negative patients with NT-proBNP <400 pg/ml and studied as well. In the pHF-positive patients followed for 3 years after starting interprofessional team approaches to prevent the onset and exacerbation of HF in the hospital, we compared the hospitalization and medical cost between the 3-year periods before and after the start of the team approaches. RESULTS
We enrolled 432 pHF-positive and 485 pHF-negative patients with one or more hospitalization records. Compared to the pHF-negative patients, the pHF-positive patients had longer total hospitalization days (median [interquartile range], 30 [13-58] versus. 18 [8-39], p <0.0001) and higher total medical cost for hospitalizations (2.42 [1.07-5.08] versus. 1.80 [0.79-3.65] million yen, p <0.0001). A subset of 303 pHF-positive patients was followed for 3 years after starting the team approaches, and we found that both total hospitalization days (30 [13-57] to 8 [0-31]) and medical cost for hospitalizations (2.59 [1.37-5.05] to 0.76 [0-2.38] million yen) showed marked reduction in them. CONCLUSIONS
Patients with an elevated serum NT-proBNP have longer hospitalizations and higher costs for all-cause hospitalizations than those without. Institutional team approaches for HF may reduce them.

Submit a Comment

Your email address will not be published. Required fields are marked *

two × one =

[ HIDE/SHOW ]